Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/E of 28.8 — elevated valuation multiple
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- Strong ROE of 21.0% with 17.4% net margin
- Revenue growing at 9% annually
ASTRAZENECA PLC (AZN) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE . Key value metrics: P/E ratio 28.8, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
ASTRAZENECA PLC — Fundamental Analysis Summary
ASTRAZENECA PLC (AZN) trades at a trailing P/E of 28.8x — 14% above the Healthcare sector average of 25.3x.
On financial health, AZN shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 21.0% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.61.
StockPik's composite Value Score for AZN is 76/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
AZN reports a high gross margin of 81.9% (sector average: 33.5%) and a strong operating margin of 23.4%.
AZN shows revenue growing at 9% year-over-year, with earnings growing at 45%.